Pharma Pulse 6/24/24: Accelerating Clinical Trial Activation, Humans Need to Be Factored Into AI Trust and Acceptance & more

Accelerating Clinical Trial Activation

The activation of each clinical trial involves hundreds of tasks, along with many dependencies and handoffs, some of which may be automated, but many require manual processes.

The Intelligence May Be Artificial but Humans Need to Be Factored Into AI Trust and Acceptance | AHIP 2024

Experts on AI spoke about strategies and tactics for implementing artificial intelligence that would assuage worries and build trust during a keynote session at AHIP annual meeting.

Operational Oversight in Clinical Research: Integrations and Insights

Learn how IQVIA’s CDAS technology and services can provide an efficient path to consolidating and harmonizing data across any provider source, ensuring high quality oversight of outsourced clinical trial activities.

If AI Is More Often Right Than Humans, Which Should We Trust? The Readers Weigh In

New advancements may mean that we turn more decision-making over to machines. Is that a good thing?

Epilepsy Drugs Market, Size, Global Research 2024-2030

The "Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global epilepsy drugs market is expected to approach approximately US$ 10.28 billion by 2030 from US$ 7.62 Billion in 2023. Between 2024 and 2030, the global epilepsy drugs market is predicted to develop at a compound annual growth rate (CAGR) of 4.37%.

Nicholas Saraceno on LinkedIn

Check out the latest podcast from Pharmaceutical Commerce Magazine - a brief, but hard-hitting chat that was hosted by my colleague, Donald Tracy, MA.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs